Study Finds Hydrochlorothiazide Ineffective in Reducing Risk of Kidney Stone Recurrence
A recent double-blind trial published in the New England Journal of Medicine explored the potential benefits of hydrochlorothiazide in preventing recurrent kidney stones. The trial randomized patients with calcium-containing kidney stones to receive hydrochlorothiazide at a dose of 12.5 mg, 25 mg, or 50 mg once daily or placebo once daily. After a median follow-up of 2.9 years, the results showed that kidney stone recurrence occurred in 59% of patients receiving hydrochlorothiazide and 59% of those receiving placebo.
The incidence of recurrence did not differ substantially among patients receiving different doses of hydrochlorothiazide.[0] Radiologic kidney stone recurrence occurred in 45%, 32%, 34%, and 49% of patients receiving 12.5 mg, 25 mg, 50 mg of hydrochlorothiazide, and placebo, respectively. Symptomatic kidney stone recurrence occurred in 38%, 40%, 28%, and 34%, respectively.
Overall, the results suggest that hydrochlorothiazide does not reduce the risk of kidney-stone recurrence.[1] However, the authors note that further studies are needed to determine if hydrochlorothiazide may be of benefit to certain subgroups of patients.
0. “Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence | NEJM” nejm.org, 1 Mar. 2023, https://www.nejm.org/doi/full/10.1056/NEJMoa2209275
1. “Daily Thiazide No Help in Preventing Recurrent Kidney Stones” Medpage Today, 1 Mar. 2023, https://www.medpagetoday.com/nephrology/generalnephrology/103336
